A university press release confirms that UPenn and its researchers ‘have received and may continue to receive significant financial benefits’ as the result of a 2018 contract with BioNTech.
Is UPenn profiting from COVID-19 vaccine approvals and sales? Read the BioNTech contract.
- Share:
